FEMYFEMASYS INC

Nasdaq femasys.com


$ 1.43 $ 0.07 (5.19 %)    

Tuesday, 07-May-2024 15:58:40 EDT
QQQ $ 437.77 $ -0.46 (-0.1 %)
DIA $ 388.70 $ 0.29 (0.07 %)
SPY $ 517.26 $ 0.57 (0.11 %)
TLT $ 90.79 $ 0.55 (0.61 %)
GLD $ 214.23 $ -0.99 (-0.46 %)
$ 1.42
$ 1.36
$ 0.00 x 0
$ 0.00 x 0
$ 1.36 - $ 1.43
$ 0.25 - $ 4.75
136,002
na
21.85M
$ 0.17
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-28-2024 12-31-2023 10-K
2 11-14-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 03-30-2023 12-31-2022 10-K
6 11-10-2022 09-30-2022 10-Q
7 08-10-2022 06-30-2022 10-Q
8 05-11-2022 03-31-2022 10-Q
9 03-24-2022 12-31-2021 10-K
10 11-12-2021 09-30-2021 10-Q
11 08-11-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 chardan-capital-maintains-buy-on-femasys-maintains-12-price-target

Chardan Capital analyst Keay Nakae maintains Femasys (NASDAQ:FEMY) with a Buy and maintains $12 price target.

 hc-wainwright--co-maintains-buy-on-femasys-raises-price-target-to-12

HC Wainwright & Co. analyst Emily Bodnar maintains Femasys (NASDAQ:FEMY) with a Buy and raises the price target from $10...

 femasys-q4-eps-019-beats-021-estimate-sales-21311k-miss-24000k-estimate

Femasys (NASDAQ:FEMY) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.21) by 9....

 chardan-capital-reiterates-buy-on-femasys-maintains-12-price-target

Chardan Capital analyst Keay Nakae reiterates Femasys (NASDAQ:FEMY) with a Buy and maintains $12 price target.

 hc-wainwright--co-reiterates-buy-on-femasys-maintains-10-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Femasys (NASDAQ:FEMY) with a Buy and maintains $10 price target.

 first-lady-jill-biden-unveils-100m-in-federal-funding-to-support-rd---watch-out-for-these-women-health-stocks

Jill Biden announces $100 million in federal funding for women's health research, addressing underfunding and lack of aware...

 femasys-inc-begins-fembloc-pivotal-trial-enrollment-at-stanford-medicine-fembloc-is-being-developed-as-a-first-
of-its-kind-non-surgical-permanent-birth-control-with-a-clearly-defined-us-regulatory-pathway

- Stanford Medicine, a center with a long tradition of leadership in pioneering gynecological research and innovation, is the s...

 femasys-inc-completes-enrollment-of-femaseed-pivotal-trial-in-support-of-commercial-launch

- Topline results from FemaSeed® pivotal trial expected in 1H 2024 - - Commercial launch planned for early 2024 -ATLANTA, Nov. ...

Core News & Articles

New investment marks expansion of corporate strategy to utilize significant cash position to create additional shareholder valu...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION